… American Academy of Optometry (AAOpt) Annual Meeting 2020 American Academy of … 2020 ProQR to participate in the American Academy of Optometry (AAOpt) Annual Meeting 2020 . wo 07-10-2020 - 00:00 …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… Team. During the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline targets for internal development, and provide guidance on the advancement of … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to advance to clinical testing in the … visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … The closing included the full exercise of underwriters’ option to purchase 2,076,923 additional shares. Gross …
… biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled … AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …